Appendix cancer other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
* The followings are among other [[Imaging studies|imaging modalities]] that may be helpful in the [[diagnosis]] and management of appendix cancer: | * The followings are among other [[Imaging studies|imaging modalities]] that may be helpful in the [[diagnosis]] and management of appendix cancer: | ||
:* [[Somatostatin]] [[scintigraphy]] with 111-indium-[[octreotide]] | :* [[Somatostatin]] [[scintigraphy]] with 111-indium-[[octreotide]]<ref name="pmid9145069">Kisker O, Bartsch D, Weinel RJ, Joseph K, Welcke UH, Zaraca F et al. (1997) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=9145069 The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.] ''J Am Coll Surg'' 184 (5):487-92. PMID: [https://pubmed.gov/9145069 9145069]</ref> | ||
::* High [[Sensitivity (tests)|sensitivity]] and [[Specificity (tests)|specificity]] for both functioning and non-functioning [[Carcinoid Tumor|carcinoid]] tumors | ::* High [[Sensitivity (tests)|sensitivity]] and [[Specificity (tests)|specificity]] for both functioning and non-functioning [[Carcinoid Tumor|carcinoid]] tumors | ||
::* Most [[Sensitivity (tests)|sensitive]] [[Imaging|imaging method to evaluate]] [[Metastases|extrahepatic metastases]] | ::* Most [[Sensitivity (tests)|sensitive]] [[Imaging|imaging method to evaluate]] [[Metastases|extrahepatic metastases]] | ||
::* Useful in treatment planning | ::* Useful in treatment planning | ||
::* Indicates response to [[Octreotide|octreotide analogues]] | ::* Indicates response to [[Octreotide|octreotide analogues]] | ||
:* [[Bone]] [[scintigraphy]] with 99mTc-methylene diphosphonate (99mTcMDP) | :* [[Bone]] [[scintigraphy]] with 99mTc-methylene diphosphonate (99mTcMDP)<ref name="pmid11158063" /> | ||
:* MIBG [[Nuclear medicine|scintigraphy]] <ref name="pmid11158063">Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. (2001) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11158063 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.] ''J Clin Endocrinol Metab'' 86 (2):895-902. [http://dx.doi.org/10.1210/jcem.86.2.7194 DOI:10.1210/jcem.86.2.7194] PMID: [https://pubmed.gov/11158063 11158063]</ref> | :* MIBG [[Nuclear medicine|scintigraphy]] <ref name="pmid11158063">Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. (2001) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11158063 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.] ''J Clin Endocrinol Metab'' 86 (2):895-902. [http://dx.doi.org/10.1210/jcem.86.2.7194 DOI:10.1210/jcem.86.2.7194] PMID: [https://pubmed.gov/11158063 11158063]</ref> | ||
::*Distinguish between primary and [[Cancer of unknown primary origin|metastatic tumors]] | ::*Distinguish between primary and [[Cancer of unknown primary origin|metastatic tumors]] | ||
Revision as of 16:46, 22 February 2019
|
Appendix cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Appendix cancer other imaging findings On the Web |
|
American Roentgen Ray Society Images of Appendix cancer other imaging findings |
|
Risk calculators and risk factors for Appendix cancer other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Positron emission tomography (PET) and scintigraphy are among other imaging modalities that may be helpful in the diagnosis and management of appendix cancer.
Other Imaging Findings
- The followings are among other imaging modalities that may be helpful in the diagnosis and management of appendix cancer:
- Somatostatin scintigraphy with 111-indium-octreotide[1]
- High sensitivity and specificity for both functioning and non-functioning carcinoid tumors
- Most sensitive imaging method to evaluate extrahepatic metastases
- Useful in treatment planning
- Indicates response to octreotide analogues
- Bone scintigraphy with 99mTc-methylene diphosphonate (99mTcMDP)[2]
- MIBG scintigraphy [2]
- Distinguish between primary and metastatic tumors
- Detecting carcinoid tumors that are negative on OctreoScan
- Positron emission tomography (PET) : Figure below demonstrates Post-operative PET-CT scan of a patient with carcinoid tumor.[3]
.jpg)
References
- ↑ Kisker O, Bartsch D, Weinel RJ, Joseph K, Welcke UH, Zaraca F et al. (1997) The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors. J Am Coll Surg 184 (5):487-92. PMID: 9145069
- ↑ 2.0 2.1 Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. (2001) Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 (2):895-902. DOI:10.1210/jcem.86.2.7194 PMID: 11158063
- ↑ Sundin A, Eriksson B, Bergström M, Långström B, Oberg K, Orlefors H (2004) PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci 1014 ():246-57. PMID: 15153441